BridgeMD
New treatment option for Cerebrovascular Disorders
Official title Statins for Treatment of Primary Intracerebral Hemorrhage
ClinicalTrials.gov ID: NCT07088250
What this study is testing
What is Atorvastatin Treatment?
Atorvastatin Treatment is an investigational medicine, given as an once-daily, being studied as a potential treatment for cerebrovascular disorders.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The STOP ICH trial is a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study designed to assess the efficacy and safety of atorvastatin in patients with intracerebral hemorrhage (ICH) presenting within 3 to 24 hours of symptom onset.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Patients with a diagnosis of spontaneous intracerebral hemorrhage (ICH) confirmed by computed tomography (CT);
- Age 18-80 years;
- Hematoma located in the supratentorial region;
- Time from symptom onset or last known well to baseline CT ranging from 3 to 24 hours;
- Atorvastatin treatment can be initiated within 48 hours of symptom onset or last known well;
You likely can't join if
- ICH secondary to trauma, tumor, aneurysm, arteriovenous malformation (AVM), vascular anomaly, hemorrhagic transformation of infarction, cerebral...
- Patients who have undergone or are scheduled for immediate surgical intervention;
- Pregnancy or lactation;
- Use of oral anticoagulants within 1 month prior to symptom onset;
- Pre-stroke mRS \>1;
- Known allergy to statins, active liver disease, liver dysfunction, or rhabdomyolysis;
See the full eligibility criteria
- Patients with a diagnosis of spontaneous intracerebral hemorrhage (ICH) confirmed by computed tomography (CT);
- Age 18-80 years;
- Hematoma located in the supratentorial region;
- Time from symptom onset or last known well to baseline CT ranging from 3 to 24 hours;
- Atorvastatin treatment can be initiated within 48 hours of symptom onset or last known well;
- Glasgow Coma Scale (GCS) score ≥9;
- Baseline hematoma volume of 5-35 mL;
- Signed informed consent obtained.
- ICH secondary to trauma, tumor, aneurysm, arteriovenous malformation (AVM), vascular anomaly, hemorrhagic transformation of infarction, cerebral venous thrombosis, or anticoagulant-related ICH;
- Patients who have undergone or are scheduled for immediate surgical intervention;
- Pregnancy or lactation;
- Use of oral anticoagulants within 1 month prior to symptom onset;
- Pre-stroke mRS \>1;
- Known allergy to statins, active liver disease, liver dysfunction, or rhabdomyolysis;
- Known terminal illness with a pre-stroke life expectancy of less than three months, or patients with planned withdrawal of care.
The study team makes the final eligibility decision.
Where it's taking place
- Anqing, Anhui, China
- Fuyang, Anhui, China
- Hefei, Anhui, China
- Huainan, Anhui, China
- Lu'an, Anhui, China
- Suzhou, Anhui, China
- Harbin, Heilongjiang, China
- Kaifeng, Henan, China
- Zhoukou, Henan, China
- Xiangyang, Hubei, China
- Chenzhou, Hunan, China
- Yancheng, Jiangsu, China
- Chengdu, Sichuan, China
- Panzhihua, Sichuan, China
- Dazhou, Sizhuan, China
- Chongqing, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Anqing, Anhui, China; Fuyang, Anhui, China; Hefei, Anhui, China; Huainan, Anhui, China; Lu'an, Anhui, China; Suzhou, Anhui, China and 10 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.